As of 2024-12-13, the Relative Valuation of SynAct Pharma AB (SYNACT.ST) is (107.98) SEK. This relative valuation is based on P/E multiples. With the latest stock price at 10.92 SEK, the upside of SynAct Pharma AB based on Relative Valuation is -1088.8%.
The range of the Relative Valuation is (91.92) - (109.82) SEK.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 24.6x - 30.8x | 30.7x |
| Forward P/E multiples | 21.6x - 29.3x | 27.0x |
| Fair Price | (91.92) - (109.82) | (107.98) |
| Upside | -941.8% - -1105.6% | -1088.8% |
| Date | P/E |
| 2024-11-29 | -3.37 |
| 2024-11-28 | -3.03 |
| 2024-11-27 | -2.67 |
| 2024-11-26 | -2.51 |
| 2024-11-25 | -2.51 |
| 2024-11-22 | -2.49 |
| 2024-11-21 | -2.48 |
| 2024-11-20 | -2.39 |
| 2024-11-19 | -2.18 |
| 2024-11-18 | -2.30 |
| 2024-11-15 | -2.40 |
| 2024-11-14 | -2.38 |
| 2024-11-13 | -2.00 |
| 2024-11-12 | -2.11 |
| 2024-11-11 | -2.08 |
| 2024-11-08 | -2.14 |
| 2024-11-07 | -2.30 |
| 2024-11-06 | -2.30 |
| 2024-11-05 | -2.32 |
| 2024-11-04 | -2.31 |
| 2024-11-01 | -2.38 |
| 2024-10-31 | -2.36 |
| 2024-10-30 | -2.35 |
| 2024-10-29 | -2.39 |
| 2024-10-28 | -2.41 |
| 2024-10-25 | -2.39 |
| 2024-10-24 | -2.38 |
| 2024-10-23 | -2.34 |
| 2024-10-22 | -2.38 |
| 2024-10-21 | -2.30 |
| 2024-10-18 | -2.33 |
| 2024-10-17 | -2.33 |
| 2024-10-16 | -2.41 |
| 2024-10-15 | -2.38 |
| 2024-10-14 | -2.36 |
| 2024-10-11 | -2.39 |
| 2024-10-10 | -2.39 |
| 2024-10-09 | -2.34 |
| 2024-10-08 | -2.43 |
| 2024-10-07 | -2.39 |
| 2024-10-04 | -2.40 |
| 2024-10-03 | -2.46 |
| 2024-10-02 | -2.39 |
| 2024-10-01 | -2.46 |
| 2024-09-30 | -2.52 |
| 2024-09-27 | -2.63 |
| 2024-09-26 | -2.68 |
| 2024-09-25 | -2.78 |
| 2024-09-24 | -2.65 |
| 2024-09-23 | -2.67 |